Fundraising FoxNeuros Medical
Aliso Viejo, US · Delaware corporation · 12 known investors
Find your way into Neuros Medical
Sign up to see every warm intro you have to Neuros Medical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neuros Medical team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees. The device targets phantom limb and residual limb pain, letting patients start therapy on demand.
Founders & leadership
DV
David VeinoPresident and CEO
ZS
Zach StassenChief Financial Officer
RJ
Robert J. CentaChief Financial Officer
Board
JE
WH
FA
CT
MM
Marc-Andre MarcotteBoard director
RB
Randy BanBoard director
CR
Claiborne R. RankinBoard director
JJ
Joseph J. JankowskiBoard director
Investors · 12
Amzak Healthlisted by Amzak HealthNew York
How we know: a partner's Signal profile · finance.yahoo.com · Not right? Tell us
APERTURE Venture Partnerslisted by APERTURE Venture PartnersNew York · $1M – $5M
How we know: APERTURE Venture Partners's portfolio page · a partner's Signal profile · finance.yahoo.com · Not right? Tell us
CWRU Technology Ventureslisted by CWRU Technology VenturesCleveland · $50K – $250K
How we know: CWRU Technology Ventures's portfolio page · Not right? Tell us
iSelect Fundlisted by iSelect FundSt. Louis · $250K – $2M
How we know: iSelect Fund's portfolio page · Not right? Tell us
JobsOhio Ventureslisted by JobsOhio VenturesColumbus
How we know: JobsOhio Ventures's portfolio page · Not right? Tell us
Jumpstart Ventureslisted by Jumpstart VenturesCleveland · $500K – $2M
How we know: Jumpstart Ventures's portfolio page · Not right? Tell us
RiverVest Venture Partnerslisted by RiverVest Venture PartnersSt. Louis · $500K – $3M
How we know: RiverVest Venture Partners's portfolio page · Not right? Tell us
US Venture Partnerslisted by US Venture PartnersMenlo Park · $500K – $10Mvia Casey Tansey · board
How we know: US Venture Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · finance.yahoo.com · Not right? Tell us
EQT Life SciencesreportedAmsterdam · $11M – $66M
How we know: a partner's Signal profile · finance.yahoo.com · Not right? Tell us
OUP (Osage University Partners)reportedBala Cynwyd · $1M – $20M
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$148.4M disclosed across 7 of 9 rounds · 2016–2025
▶$56MraisedAug 2025 · 28 investors · BiotechnologyRule 506(b)
▶$56MraisedAug 2025 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David VeinoExecutive Officer, Director
- Joyce EronyDirector
- William HarringtonDirector
- Fouad AzzamDirector
- Zach StassenExecutive Officer
- Casey TanseyDirector
- Marc-Andre MarcotteDirector
- Randy BanDirector
- Offering amount
- $65M
- Amount sold
- $56M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedSep 2023 · 41 investors · BiotechnologyRule 506(b)
▶$20MraisedSep 2023 · 41 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William HarringtonDirector
- Marc-Andre MarcotteDirector
- Casey TanseyDirector
- Anthony NataleDirector
- Thomas C. WilderExecutive Officer, Director
- Joyce EronyDirector
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.2MraisedDec 2022 · 40 investors · BiotechnologyRule 506(b)
▶$8.2MraisedDec 2022 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joyce EronyDirector
- Thomas C. WilderExecutive Officer, Director
- William HarringtonDirector
- Anthony NataleDirector
- Casey TanseyDirector
- Marc-Andre MarcotteDirector
- Offering amount
- $10M
- Amount sold
- $8.2M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$37MraisedNov 2020 · 24 investors · BiotechnologyRule 506(b)
▶$37MraisedNov 2020 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas C. WilderExecutive Officer, Director
- Casey TanseyDirector
- William HarringtonDirector
- Anthony NataleDirector
- Marc-Andre MarcotteDirector
- Joyce EronyDirector
- Offering amount
- $42.8M
- Amount sold
- $37M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedJun 2020 · 5 investors · BiotechnologyRule 506(b)
▶$2.2MraisedJun 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William HarringtonDirector
- Casey TanseyDirector
- Thomas C. WilderExecutive Officer, Director
- Anthony NataleDirector
- Offering amount
- $5.5M
- Amount sold
- $2.2M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedOct 2019 · 4 investors · BiotechnologyRule 506(b)
▶$2.4MraisedOct 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas C. WilderExecutive Officer, Director
- William HarringtonDirector
- Casey TanseyDirector
- Anthony NataleDirector
- Offering amount
- $9.2M
- Amount sold
- $2.4M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedAug 2017 · 55 investors · BiotechnologyRule 506(c)
▶Undisclosed amountofferedAug 2017 · 55 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Anthony NataleDirector
- William HarringtonDirector
- Casey TanseyDirector
- Jon J. SnyderExecutive Officer, Director
- Alan KaganovDirector
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$22.6MraisedAug 2017 · 27 investors · BiotechnologyRule 506(c)
▶$22.6MraisedAug 2017 · 27 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Anthony NataleDirector
- Alan KaganovDirector
- William HarringtonDirector
- Jon J. SnyderExecutive Officer, Director
- Casey TanseyDirector
- Offering amount
- $22.7M
- Amount sold
- $22.6M
- Minimum investment
- $16.7K
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
ToperaAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
Boston ScientificBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Noctrix HealthNoctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes. The company targets patients living with chronic conditions such as restless legs syndrome, offering prescription-grade therapy through medical devices.
Companies working in the same space as Neuros Medical.
In the news
Frequently asked questions
- What does Neuros Medical do?
- Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees. The device targets phantom limb and residual limb pain, letting patients start therapy on demand.
- Who are Neuros Medical's investors?
- Neuros Medical's investors include Amzak Health, APERTURE Venture Partners, CWRU Technology Ventures, iSelect Fund, JobsOhio Ventures, Jumpstart Ventures, RiverVest Venture Partners, US Venture Partners and 4 more.
- How much funding has Neuros Medical raised?
- Neuros Medical has disclosed $148.4M raised across 7 of its 9 known rounds.
- Where is Neuros Medical headquartered?
- Neuros Medical is headquartered in Aliso Viejo, US.